The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Drugs and their molecular targets: an updated overview
Abstract
About 330 targets bind approved drugs, 270 encoded by the human genome and 60 belonging to pathogenic organisms. A large number of druggable targets have been recently proposed from preclinical and first clinical data, but a huge reservoir of putative drug targets, possibly several thousands, remains to be explored. This overview considers the different types of ligands and their selectivity in the main superfamilies of drug targets, enzymes, membrane transporters and ion channels, and the various classes of membrane and nuclear receptors with their signalling pathway. Recently approved drugs such as monoclonal antibodies, tyrosine kinase and proteasome inhibitors, and major drugs under clinical studies are reviewed with their molecular target and therapeutic interest. The druggability of emerging targets is discussed, such as multidrug resistance transporters and cystic fibrosis transmembrane conductance regulator (CFTR), hyperpolarization‐activated cyclic nucleotides‐gated (HCN), cyclic nucleotide‐gated (CNG) and transient receptor potential (TRP) ion channels, tumour necrosis factor (TNF) and receptor activator of NFκB (RANK) receptors, integrins, and orphan or recently deorphanized G‐protein‐coupled and nuclear receptors. Large advances have been made in the therapeutical use of recombinant cytokines and growth factors (i.e. tasonermin, TNFα‐1a; becaplermin, platelet‐derived growth factor (PDGF); dibotermin‐alpha, bone morphogenetic proteins (BMP)2; anakinra, interleukin‐1 receptor antagonist protein (IRAP), and in enzyme replacement therapy, i.e. algasidase (alpha‐galactosidase) and laronidase (alpha‐l‐iduronidase). New receptor classes are emerging, e.g. membrane aminopeptidases, and novel concepts are stimulating drug research, e.g. epigenetic therapy, but the molecular target of some approved drugs, such as paracetamol and imidazolines, still need to be identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
NMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Cited by
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
Drug–target interaction prediction by random walk on the heterogeneous network
Chen, X., Liu, M.-X., & Yan, G.-Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb00002d · Cited by 533
Predicting druggable binding sites at the protein–protein interface
Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 310
Reiner, Ž., Sonicki, Z., & Tedeschi-Reiner, E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.014 · Cited by 148
Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey
Reiner, Ž., Sonicki, Z., & Tedeschi-Reiner, E. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.09.015 · Cited by 73
Metadata
- Authors
- Landry, Y., & Gies, J.
- Venue
- Fundamental & Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2008-01-30
- Volume
- 22
- Issue
- 1
- Pages
- 1-18
- ISSN
- 0767-3981 (ISSN-L)
- 1472-8206
- OpenAlex
- W2029152175
- Cited by
- 208
- References
- 4
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drugs and their molecular targets: an updated overview. https://app.cochat.ai/papers/10.1111/j.1472-8206.2007.00548.x
- The paper
- Landry, Y., & Gies, J. (2008). Drugs and their molecular targets: an updated overview. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.2007.00548.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.